An approach called synthetic lethality targets biological systems in which two or more genetic pathways interact to contribute to a vital cellular process. The loss of either pathway does not threaten cell viability and may indeed provide a survival advantage, such as the case with cancer cells; however, lethality is observed when both pathways are inhibited, which may be achieved using specific inhibitory compounds. ACRI scientists are working to identify the pathways in cancer cells that can elicit synthetic lethality and develop compounds that can take advantage of these discoveries. These experiments should lead to compounds that target only cancer cells (which already have loss-of-function in one pathway) and have no effect on normal cells, thus avoiding the side effects associated with current therapies.
- Eric Merzetti, Ph. D.
- Nichole Cumby, Ph. D.
- Pierre Desprez, Ph. D.
- Charles Buellerwell, Ph. D.
- Sonia D'astous, Ph. D.
- Nadia Bouhamdani, Ph. D.
- Dominique Comeau, Ms. C
- Laura Ayre
- Dr Sandra Turcotte
